iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Clinical and IT Experts from Wake Radiology
Leading healthcare provider with 14 imaging
centers in North Carolina identified ProFound AI as the premier solution in a competitive
trial based on unique workflow benefits and multivendor flexibility
NASHUA, N.H. – April 28, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing
innovative cancer detection and therapy solutions, today announced that the
next event in its “ProFound Insights, ProFound Impact” webinar series will
take place on Tuesday, May 10 at 7 pm EST. The live event,
titled “Why ProFound AI® Prevailed as the Premier AI Solution in a
Competitive Trial at Wake Radiology,” will feature clinical
and information technology (IT) experts from Wake Radiology, a leading
healthcare provider with 14 imaging locations in the Raleigh-Durham metropolitan
area. The event will be moderated by iCAD’s President and CEO, Stacey Stevens.
Visit this
link to register.
Featured panelists include:
- Matt Dewey, Chief Information Officer (CIO),
Wake Radiology - William G. Way Jr., MD, Diagnostic Radiologist, Wake
Radiology
“After
comparing all available options, we felt that iCAD’s technology was simply the
best. We needed an AI solution that would allow us to read mammograms from
either the Hologic workstation
or from Intelerad PACS and ProFound AI, which supports multiple output formats,
was able to provide that flexibility.” — Matt Dewey, CIO, Wake Radiology
“Having the
latest in AI at our fingertips shows that we are on the leading edge of
advances in breast imaging. It inspires confidence in our patients that we are
committed to the deployment of state-of-the-art technologies that are
clinically proven to enhance patient care.” — William G. Way Jr., MD,
Diagnostic Radiologist, Wake Radiology
The Company’s “ProFound Insights, ProFound Impact” webinar series, which will highlight customer success
stories throughout the year, began on Wednesday,
April 27. The first event,
“Why Kettering Health Traded out Previous AI Software for ProFound AI®
Enterprise-Wide” featured distinguished clinical and administrative experts
from Kettering Health, a leading enterprise breast care provider with 14 breast
centers across southwest Ohio. Event recordings are available on the Company’s
website, www.icadmed.com.
About iCAD, Inc.
Headquartered in
Nashua, NH, iCAD® is a global medical technology leader providing innovative
cancer detection and therapy solutions. For more information, visit www.icadmed.com.
Forward-Looking Statements
Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995, including statements about the expected benefits
of ProFound AI®, the benefits of the Company’s products, and future prospects
for the Company’s technology platforms and products. Such forward-looking
statements involve a number of known and unknown risks, uncertainties and other
factors which may cause the actual results, performance, or achievements of the
Company to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking statements. Such
factors include, but are not limited, to the Company’s ability to achieve
business and strategic objectives, the willingness of patients to undergo
mammography screening in light of risks of potential exposure to Covid-19,
whether mammography screening will be treated as an essential procedure,
whether ProFound AI will improve reading efficiency, improve specificity and
sensitivity, reduce false positives and otherwise prove to be more beneficial
for patients and clinicians, the impact of supply and manufacturing constraints
or difficulties on our ability to fulfill our orders, uncertainty of future
sales levels, to defend itself in litigation matters, protection of patents and
other proprietary rights, product market acceptance, possible technological
obsolescence of products, increased competition, government regulation, changes
in Medicare or other reimbursement policies, risks relating to our existing and
future debt obligations, competitive factors, the effects of a decline in the
economy or markets served by the Company; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates
to any information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the disclosure contained
in our public filings with the Securities and Exchange Commission, available on
the Investors section of our website at http://www.icadmed.com and on the SEC’s
website at http://www.sec.gov.
Contact:
Media
Inquiries:
Jessica
Burns, iCAD
+1-201-423-4492
Investor
Inquiries:
iCAD
Investor Relations